Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
Starting a GLP-1 receptor agonist often causes performance dips during the first 4–6 weeks. Reduced calorie intake, mild GI side effects, and shifts in fluid and electrolytes leave muscles under-fueled, resulting in cardio fatigue, lower strength in resistance training, and a greater need for careful fueling and hydration.
Key strategies to maintain workout energy include:
If fatigue, weakness, or GI symptoms feel more intense than expected, it's worth understanding whether they're typical GLP-1 side effects or signs of something else—like dehydration, low blood sugar, or nutrient deficiency. A free, instant, online symptom check can help you identify what's driving your symptoms and clarify your next steps, so you can train smarter and recover faster.
Reviewed for medical accuracy: 07/02/2026
Starting a GLP-1 (glucagon-like peptide-1) receptor agonist can be a game-changer for weight management and blood sugar control. However, many people notice a temporary drop in exercise energy levels when they first begin treatment. This guide explains why that happens and offers practical tips to help you stay active and energized.
GLP-1 medications—such as semaglutide (Wegovy®, Ozempic®) and liraglutide (Saxenda®)—work by:
These effects bring powerful benefits for weight loss and metabolic health, but they can also temporarily alter how you feel during workouts.
Common early changes include:
All of these can contribute to a dip in exercise energy levels, especially in the first 4–6 weeks after your dose is increased.
Because GLP-1s curb your appetite, you may naturally eat less. If your body isn't used to that change, you might notice:
When calorie intake drops abruptly, your muscles have less fuel. This is especially true if you're not paying attention to macronutrient balance or meal timing around workouts.
Early gastrointestinal side effects—nausea, bloating, mild diarrhea—can also play a role:
Staying adequately hydrated and replenishing electrolytes is crucial to maintaining exercise energy levels while your body adjusts.
You don't have to let performance dips derail your fitness goals. Try these evidence-based tactics:
Your body will adapt to GLP-1 therapy, and energy levels generally improve after the initial adjustment period. Keep these principles in mind:
By 6–12 weeks, most people regain stable exercise energy levels while enjoying the benefits of improved appetite control and metabolic health.
If you experience severe or persistent symptoms—such as ongoing nausea that prevents adequate nutrition, extreme fatigue, or signs of dehydration—it's important to get personalized guidance. Try Ubie's free AI-powered Medically Approved Symptom Checker Chat Bot to quickly assess your symptoms and understand whether you need urgent care or can wait for a scheduled appointment.
Above all, speak to a doctor if you notice any potentially life-threatening issues or have serious concerns about your health.
Maintaining your fitness and performance while starting GLP-1 therapy is doable with the right approach. By fine-tuning nutrition, hydration, and exercise programming, you can minimize dips in exercise energy levels and continue making progress toward your health goals. Always consult your healthcare provider before making significant changes to your medication, diet, or exercise plan.
(References)
* Li J, Deng Y, Qin B, Gao Y, Chen X, Liang T. Impact of GLP-1 receptor agonists on exercise tolerance and physical activity in patients with type 2 diabetes and obesity: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2022 May;187:109886. doi: 10.1016/j.diabres.2022.109886. Epub 2022 Apr 15. PMID: 35436663.
* Nauck MA, Meier JJ. Gastrointestinal adverse events with GLP-1 receptor agonists: mechanisms and management. Diabetes Obes Metab. 2021 May;23 Suppl 1:12-29. doi: 10.1111/dom.14321. PMID: 33792900.
* Vilsbøll T, Marre M, Nauck MA. Effect of GLP-1 receptor agonists on body weight and composition, energy expenditure and physical activity in overweight and obese individuals. Diabetologia. 2022 Jan;65(1):7-23. doi: 10.1007/s00125-021-05561-1. Epub 2021 Sep 24. PMID: 34561763.
* Sarmento G, Valdovinos-García A, Flores-Castillo D, Rosas-Saucedo JE. Tirzepatide and semaglutide effect on exercise capacity, physical activity, and symptoms in individuals with obesity: a narrative review. Front Endocrinol (Lausanne). 2023 Dec 11;14:1310185. doi: 10.3389/fendo.2023.1310185. PMID: 38148897; PMCID: PMC10746979.
* Wilding JPH, Batterham RL, Blickwedehl J, Boughton K, Brancati FL, Frias JP, Holst AG, Jensen C, Kahn SE, Klonoff DC, Leiter LA, Meier JJ, Mosenzon O, Nauck MA, Reasner CA, Rodbard HW, Rosenstock J, Sesti G, Simpson R, Tsigos C, Wadden TA, Wharton S, Davies M. Practical considerations for initiation and titration of glucagon-like peptide-1 receptor agonists for weight management. Obes Facts. 2022;15(4):599-612. doi: 10.1159/000524458. Epub 2022 May 24. PMID: 35738202; PMCID: PMC9283995.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.